According to the recent research report titled ‘Asia Pacific Breast Cancer Therapeutics Market Forecast 2028 By Therapy, Research Report, Country Outlook, COVID-19 Impact Statistics, Price Trends, Historic Data, Growth Prospects, Competitive Industry Share’ available in MarketStudyReport, Asia Pacific breast cancer therapeutics market accounted for USD 3 billion in 2021 and is predicted to value USD 7.5 billion by 2028.

The major factors driving the Asia Pacific breast cancer therapeutics market growth are expanding medical services, increased medical coverage, and rapid advancements in research & treatments. Growing prevalence of breast cancer and introduction of novel screen and diagnostic programs are also aiding towards the market expansion.

Request sample copy of this report: https://www.marketstudyreport.com/request-a-sample/4966051/  

For the last few decades, breast cancer has been a severe health concern across Asia Pacific. Despite tremendous progress in cutting breast cancer mortality in many high-income countries, low- and middle-income countries have made little progress.

According to the WHO, breast cancer survival rates in high-income countries are currently above 80%, compared to 66% in India and only 40% in South Africa five years following diagnosis. This cancer type has also surpassed lung cancer as the most commonly diagnosed cancer in the world, accounting for one in every six-cancer death among women, according to statistics issued by the International Agency for Research on Cancer (IARC) in December 2020.

Based on therapy type, Asia Pacific breast cancer therapeutics marketplace is segmented into chemotherapy, targeted therapy, hormonal therapy, and immunotherapy.

According to the report, these treatments may be able to delay chemotherapy which, in turn, help patients live longer. The FDA recently has approved palbociclib, ribociclib, and everolimus for use in conjunction with hormone treatment to treat advanced or metastatic breast cancer.

The regional landscape of the Asia Pacific breast cancer therapeutics industry is spans across China, India, Australia, South Korea, Japan, Thailand, Philippines, Indonesia New Zealand, Malaysia, and Singapore. Given the rising demand for sophisticated cancer care, breast cancer therapeutics market size in China is expected to value USD 1.9 billion by 2028. 

More than two-thirds of breast cancer patients in China are diagnosed at advanced stages. The Chinese government has also prioritized tariff reductions as well as the importation of newly discovered pharmaceuticals and their inclusion in the country's public health insurance system.

The leading companies defining the competitive landscape of Asia Pacific breast cancer business space are Eisai Co. Ltd, Sanofi S.A., Merck & Co. Inc., F. Hoffmann-La Roche AG, Amgen Inc., Novartis International AG, Bristol-Myers Squibb Co., Pfizer Inc., Eli Lilly and Company, and AstraZeneca plc.